tauroursodeoxycholic

DRUG2 trials

Sponsors

Beijing Trendful Kangjian Medical Information Consulting Limited Company, Humanitas Mirasole SpA

Conditions

ALSCholestatic Liver Disease

Phase 3

Efficacy and Safety Study of TUDCA Compare UDCA to Treatment Chronic Cholestatic Liver Disease-PBC

CompletedNCT01829698

Beijing Trendful Kangjian Medical Information Consulting Limited CompanyCholestatic Liver Disease

Start: 2009-08-31End: 2014-02-28Updated: 2014-03-24

Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS)

Active, not recruitingNL-OMON55527

Humanitas Mirasole SpAALS

Start: 2019-12-11Target: 20Updated: 2025-09-01